Precede Biosciences
Precede Biosciences is dedicated to breaking down barriers to precision medicine by providing unprecedented insights into disease biology from a simple blood test. Their platform uncovers the activation status of therapeutically actionable genes and pathways, enabling more precise diagnosis and treatment. They aim to improve success rates in drug development and clinical practice by offering minimally invasive, rapid diagnostics that are tailored to the biology of each patient's disease.
Industries
Nr. of Employees
small (1-50)
Precede Biosciences
Boston, Massachusetts, United States, North America
Products
Liquid Biopsy Platform
A platform that profiles circulating chromatin and the DNA methylome from 1mL of plasma to provide resolution into the activation status of genes and pathways.
Epigenomic Profiling Assay
An assay that reveals disease biology and therapeutic targets from 1mL of plasma, used for cancer research and therapy selection.
Blood-Based Diagnostic Tests
Tests developed using the liquid biopsy platform to provide precision use of cancer medicines, offering a minimally invasive alternative to tissue biopsies.
Research Use Only (RUO) Platform
A version of the liquid biopsy platform available to drug developers and academic researchers for research purposes.
Liquid Biopsy Platform
A platform that profiles circulating chromatin and the DNA methylome from 1mL of plasma to provide resolution into the activation status of genes and pathways.
Epigenomic Profiling Assay
An assay that reveals disease biology and therapeutic targets from 1mL of plasma, used for cancer research and therapy selection.
Blood-Based Diagnostic Tests
Tests developed using the liquid biopsy platform to provide precision use of cancer medicines, offering a minimally invasive alternative to tissue biopsies.
Research Use Only (RUO) Platform
A version of the liquid biopsy platform available to drug developers and academic researchers for research purposes.
Services
Liquid Biopsy Platform Development
Development of a comprehensive genome-wide liquid biopsy platform profiling circulating chromatin and DNA methylome from plasma.
Blood-based Diagnostic Tests
Development of blood-based tests for the precision use of cancer medicines, reducing reliance on invasive tissue biopsies.
Liquid Biopsy Platform Development
Development of a comprehensive genome-wide liquid biopsy platform profiling circulating chromatin and DNA methylome from plasma.
Blood-based Diagnostic Tests
Development of blood-based tests for the precision use of cancer medicines, reducing reliance on invasive tissue biopsies.